GC4419 IV

DRUG2 trials

Sponsors

Galera Therapeutics, Inc.

Conditions

HealthyHealthy VolunteerHealthy Volunteers

Phase 1

A Study of the Safety, Tolerability and Pharmacokinetics of Orally-administered GC4702 in Healthy Volunteers

CompletedNCT03096756

Galera Therapeutics, Inc.Healthy Volunteer

Start: 2016-07-26End: 2016-12-31Updated: 2017-04-04

A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers

CompletedNCT03164109

Galera Therapeutics, Inc.Healthy, Healthy Volunteers

Start: 2017-08-18End: 2017-10-13Updated: 2017-11-17